Drug intelligence / Profile preview

AB004

Development stage: Preclinical
Lead developer: AKSO Biotechnology
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes

Overview

AB004 (also known as AB-004) is a preclinical-stage bispecific fusion protein trap developed by AKSO Biotechnology. It is designed to simultaneously target and neutralize the signaling of a proliferation-inducing ligand (APRIL), B-cell activating factor (BAFF), and interleukin-11 (IL-11). By blocking these pathways, AB004 aims to reduce both immune-mediated inflammatory responses and fibrotic processes. The therapeutic candidate is currently undergoing lead optimization for the potential treatment of chronic kidney disease (CKD), nonalcoholic steatohepatitis (NASH), and idiopathic pulmonary fibrosis (IPF).

Targets

IL11 (Interleukin-11)TNFSF13 (APRIL)BAFF (Tumor necrosis factor ligand superfamily member 13B)

Beyond the preview

Go deeper on AB004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AB004.